Intravesical chemotherapy with epirubicin: A dose response study

Journal of Urology

Volumn 161, Issue 5, 1999, Pages 1490-1493

  Masters, John R W ^a   Popert, Richard J M ^a   Thompson, Peter M ^a   Gibson, Della ^a   Coptcoat, Malcolm J ^a   Parmar, Mahesh K B ^a  

^a NONE

Author keywords

Bladder neoplasms; Dose response relationship, drug; Epirubicin

Indexed keywords

EPIRUBICIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK;

EID: 0032875805     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68935-5     Document Type: Article

References (20)

1. Schabel, F. M., Griswold, D. P., Corbett, T. H. and Laster, W. R.: Increasing therapeutic rates to anticancer drugs by applying the basic principles of pharmacology. Pharmacol. Ther., 20: 283, 1983.
2. Gurney, H., Dodwell, D. and Thatcher, N.: Escalating drug delivery in cancer chemotherapy: a review of concepts and practice - Part 1. Ann. Oncol., 4: 23, 1993.
3. Gurney, H., Dodwell, D. and Thatcher, N.: Escalating drug delivery in cancer chemotherapy: a review of concepts and practice - Part 2. Ann. Oncol., 4: 103, 1993.
4. Dodwell, D. J., Gurney, H. and Thatcher, N.: Dose intensity in cancer chemotherapy. Brit. J. Cancer, 61: 789, 1990.
5. Sweetenham, J. W.: The importance of dose and schedule in cancer chemotherapy: haematological cancer. Anti-Cancer Drugs, suppl., 6: 7, 1995.
6. Leonard, R. C. F.: The importance of dose and schedule in cancer chemotherapy: breast cancer. Anti-Cancer Drugs, suppl., 6: 17, 1995.
7. Mainwaring, P. N. and Gore, M. E.: The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer. Anti-Cancer Drugs, suppl., 6: 29, 1995.
8. De Mulder, P. H. M. and de Wit, R.: Experience with dose and schedule variations in germ cell tumors. Anti-Cancer Drugs, suppl., 6: 43, 1995.
9. Ranson, M. and Thatcher, N.: The importance of dose and schedule in chemotherapy for small cell lung cancer. Anti-Cancer Drugs, suppl., 6: 53, 1995.
10. Altman, D. G.: Practical Statistics for Medical Research. London: Chapman and Hall, 1991.
11. Parmar, M. K. B. and Machin, D.: Survival Analysis. A Practical Approach. Chichester: John Wiley & Sons, pp. 65-96, 1995.
12. Freedman, L. S., Spiegelhalter, D. J. and Parmar, M. K.: The what, why and how of Bayesian clinical trial monitoring. Stat. Med., 13: 1371, 1994.
13. Popert, R. J. M., Goodall, J. and Coptcoat, M.: Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin. Brit. J. Urol., 74: 195, 1994.
14. Jones, H. C. and Swinney, J.: Thiotepa in the treatment of tumours of the bladder. Lancet, 2: 615, 1961.
15. Koontz, W. W., Prout, G. R. and Smith, W.: The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder. J. Urol., 125: 307, 1981.
16. De Bruijn, E. A., Sleeboom, H. P. and van Helsingden, P. J. R. O.: Pharmacodynamics and pharmacokinetics of intravesical mitomycin c upon different dwelling times. Int. J. Cancer, 51: 359, 1992.
17. Bracken, R. B., Swanson, D. A. and Johnson, D. E.: Role of intravesical mitomycin C in management of superficial bladder tumors. Urology, 16: 11, 1980.
18. Bastholt, L., Dalmark, M. and Gjedde, S. B.: Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish breast cancer cooperative group. J. Clin. Oncol., 14: 1146, 1996.
19. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer.: The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Brit. J. Urol., 73: 632, 1994.
20. Igawa, M., Urakami, S. and Shirakawa, H.: Intravesical instillation of epirubicin: effect on tumour recurrence in patients with dysplastic epithelium after transurethral resection of superficial bladder tumour. Brit. J. Urol., 77: 358, 1996.